{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:54:05Z","timestamp":1793328845425,"version":"4.5.0"},"reference-count":33,"publisher":"Society of Nuclear Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.2967\/jnumed.119.236414","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T20:49:13Z","timestamp":1573850953000},"page":"857-865","source":"Crossref","is-referenced-by-count":272,"title":["Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of\n                    <sup>177<\/sup>\n                    Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.2967","volume":"61","author":[{"given":"John","family":"Violet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahneen","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Iravani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Ferdinandus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue-Ping","family":"Thang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravind Ravi","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Akhurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pattison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Beaulieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Mooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Kalff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan G","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Price","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Eu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Scalzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney J.","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2019,11,15]]},"reference":[{"key":"2021051712145261000_61.6.857.1","first-page":"5237","article-title":"In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen","volume":"60","author":"Smith-Jones","year":"2000","journal-title":"Cancer Res."},{"key":"2021051712145261000_61.6.857.2","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.10661"},{"key":"2021051712145261000_61.6.857.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00278-7"},{"key":"2021051712145261000_61.6.857.4","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bju.14374","article-title":"A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET\/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol","volume":"122","author":"Hofman","year":"2018","journal-title":"BJU Int."},{"key":"2021051712145261000_61.6.857.5","doi-asserted-by":"crossref","unstructured":"Perera M Papa N Roberts M . Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions\u2014a systematic review and meta-analysis. Eur Urol. February 14, 2019 [Epub ahead of print].","DOI":"10.1016\/j.eururo.2019.01.049"},{"key":"2021051712145261000_61.6.857.6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.euo.2019.01.001","article-title":"Theranostics for advanced prostate cancer: current indications and future developments","volume":"2","author":"Farolfi","year":"2019","journal-title":"Eur Urol Oncol."},{"key":"2021051712145261000_61.6.857.7","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13550-015-0114-2","article-title":"Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study","volume":"5","author":"Ahmadzadehfar","year":"2015","journal-title":"EJNMMI Res."},{"key":"2021051712145261000_61.6.857.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.183194"},{"key":"2021051712145261000_61.6.857.9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00259-016-3481-7","article-title":"177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment","volume":"44","author":"Yadav","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021051712145261000_61.6.857.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.02.2969"},{"key":"2021051712145261000_61.6.857.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.168443"},{"key":"2021051712145261000_61.6.857.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.170167"},{"key":"2021051712145261000_61.6.857.13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clgc.2018.09.014","article-title":"Results of a prospective phase 2 pilot trial of 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression","volume":"17","author":"Emmett","year":"2019","journal-title":"Clin Genitourin Cancer."},{"key":"2021051712145261000_61.6.857.14","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol."},{"key":"2021051712145261000_61.6.857.15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219352"},{"key":"2021051712145261000_61.6.857.16","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-016-0942-0"},{"key":"2021051712145261000_61.6.857.17","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3174-7"},{"key":"2021051712145261000_61.6.857.18","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3125-3"},{"key":"2021051712145261000_61.6.857.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178483"},{"key":"2021051712145261000_61.6.857.20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MNM.0000000000000606","article-title":"Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer","volume":"38","author":"Yadav","year":"2017","journal-title":"Nucl Med Commun."},{"key":"2021051712145261000_61.6.857.21","first-page":"123","article-title":"177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer [in German]","volume":"55","author":"Fendler","year":"2016","journal-title":"Nucl Med (Stuttg)."},{"key":"2021051712145261000_61.6.857.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2021051712145261000_61.6.857.23","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"2021051712145261000_61.6.857.24","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singapore."},{"key":"2021051712145261000_61.6.857.25","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-013-2621-6"},{"key":"2021051712145261000_61.6.857.26","first-page":"670","article-title":"Poor outcomes for patients with metastatic castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for 177Lu-labelled PSMA radioligand therapy","volume-title":"Eur Urol Oncol.","volume":"2","author":"Thang","year":"2019"},{"key":"2021051712145261000_61.6.857.27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.171397"},{"key":"2021051712145261000_61.6.857.28","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00259-016-3481-7","article-title":"177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment","volume":"44","author":"Yadav","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021051712145261000_61.6.857.29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/RLU.0000000000002575","article-title":"Pretherapeutic 68Ga-PSMA-617 PET may indicate the dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in main organs and tumor lesions","volume":"44","author":"Wang","year":"2019","journal-title":"Clin Nucl Med."},{"key":"2021051712145261000_61.6.857.30","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","article-title":"Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer","volume":"76","author":"Paschalis","year":"2019","journal-title":"Eur Urol."},{"key":"2021051712145261000_61.6.857.31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.euo.2019.03.004","article-title":"Where to next for theranostics in prostate cancer?","volume":"2","author":"Murphy","year":"2019","journal-title":"Eur Urol Oncol."},{"key":"2021051712145261000_61.6.857.32","doi-asserted-by":"crossref","unstructured":"Murphy DG Hofman MS Azad A Violet J Hicks RJ Lawrentschuk N . Going nuclear: it is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team. BJU Int. May 24, 2019 [Epub ahead of print].","DOI":"10.1111\/bju.14814"},{"key":"2021051712145261000_61.6.857.33","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.057307"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.119.236414","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T16:50:18Z","timestamp":1621270218000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.119.236414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,15]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6,4]]},"published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.2967\/jnumed.119.236414"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.119.236414","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,15]]}}}